系统性硬化症相关肺动脉高压患者的再住院情况:PHAROS登记研究结果
基于PHAROS登记中572例SSc-PH患者的数据,54%在2005至2016年间至少有1次住院,曾住院者中34%发生12个月内再住院。与PH或SSc相关的索引住院增加再住院风险,家庭氧疗使用与再住院风险降低相关。
要点
- 索引住院与PH相关者12个月再住院风险显著升高(aOR 6.6)。
- 家庭氧疗使用者再住院风险较低(aOR 0.44)。
- 种族、年龄、性别、病程及疾病亚型与再住院无关。
核心结论
- 12个月再住院的最强预测因素是索引住院原因与PH相关。
- 家庭氧疗使用与较低的再住院风险相关。
研究设计与样本
- 基于PHAROS登记的前瞻性队列研究,纳入572例SSc-PH患者,收集临床数据及住院信息。
- 再住院定义为任何出院后12个月内的再次住院,采用Fisher精确检验、Wilcoxon秩和检验或Kruskal-Wallis检验比较特征,逻辑回归评估预测因素与再住院的关联。
主要发现
- 572例SSc-PH患者中54%在2005至2016年间至少有1次住院,曾住院者中34%发生至少1次再住院。
- 有再住院者与无再住院者相比,索引住院日期至下次PHAROS访视的中位时间更短[37(3,80)天 vs 81(42,136)天,P<0.001]。
- 索引住院与PH相关(vs非PH/SSc相关)的12个月再住院aOR为6.6(95%CI 3.2,13.6),与SSc相关(vs非PH/SSc相关)的aOR为2.2(95%CI 1.1,4.5)。
- 家庭氧疗使用者(vs非使用者)再住院的aOR为0.44(95%CI 0.22,0.89)。
- 种族、年龄、性别、病程和疾病亚型与再住院无关。
临床怎么用
- 对SSc-PH患者应关注索引住院原因,尤其PH相关住院者再住院风险高。
- 可评估家庭氧疗需求,其使用与再住院风险降低相关。
局限性
- 研究为观察性设计,无法确定家庭氧疗与再住院风险的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify individual-level factors associated with hospital readmission among individuals with SSc-associated pulmonary hypertension (SSc-PH). METHODS: Individuals enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry contributed clinical data related to SSc-PH disease severity and hospital admissions. Readmission was defined as a subsequent hospitalization within 12 months of any hospital discharge. Characteristics were compared between individuals with and without readmissions using Fisher's exact test, Wilcoxon rank-sum test, or Kruskal-Wallis test. Logistic regression was used to estimate associations between clinical predictors and likelihood of readmission. RESULTS: Of 572 individuals with SSc-PH enrolled in PHAROS, 54% had ≥1 hospitalizations between 2005 and 2016. Among individuals ever-hospitalized, 34% had ≥1 readmission. Individuals with vs without readmissions had shorter median (IQR) time between index hospitalization date and next PHAROS visit [37 (3, 80) vs 81 (42, 136) days, P <0.001]. Index admissions related to PH or SSc (vs non-PH/SSc related) were associated with an increased odds of 12-month readmission [aOR 6.6 (95% CI 3.2, 13.6) and aOR 2.2 (95% CI 1.1, 4.5), respectively]. Readmission was less likely among home oxygen users (vs non-users) (aOR 0.44; 95% CI 0.22, 0.89). Race, age, sex, disease duration and disease subtype were not associated with readmission. CONCLUSION: The strongest predictor for 12-month readmission was an index hospitalization reason related to PH. Home oxygen use was associated with lower odds of readmission. Future studies should determine whether testing for the need for home oxygen mediates the risk of readmission in SSc-PH.
引用
- Showalter K, Pinheiro LC, Jannat-Khah D, et al. Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry. Rheumatology (Oxford). 2022. PMID: 34273167. doi:10.1093/rheumatology/keab569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。